Posted in | News | Nanomedicine | Nanobusiness

NanoString Announces Collaboration with Broad Institute of MIT and Harvard

NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced that it is collaborating with the Broad Institute of MIT and Harvard to investigate molecular networks involved in immune response and other important biological processes. The three-year collaboration is also designed to explore ways to expand how NanoString's next-generation digital gene expression technology can be applied to improve basic and clinical research.

As part of the collaboration, the Broad Institute will use NanoString's nCounterTM Analysis System to decipher entire networks of genes to identify how these genes work together to carry out biological functions. To support this effort, NanoString will design custom CodeSets (molecular barcodes associated with the genes of interest) based on gene signatures identified by Broad investigators. These gene sets may eventually be developed into commercially available assay panels for the nCounter system.

“NanoString offers the ability to look at hundreds of genetic markers across many samples at relatively low cost and with high sensitivity. They have developed exciting technology with potential applications to a wide range of scientific problems,” said Eric Lander, D. Phil., Director of the Broad Institute. “We look forward to working together to explore new ways of using of this technology.”

Last month, scientists at the Broad Institute, NanoString, and Massachusetts General Hospital published a first-of-its-kind study in Science Express that demonstrated the nCounter's ability to elucidate complex circuitry involved in pathogen recognition in mammalian cells. The study also offered a practical approach for unraveling the gene networks that underpin other important biological systems.1

The current collaboration will expand upon this published work, and explore additional gene networks involved in innate and adaptive immunity, stem cell differentiation and non-coding RNA function, including the regulatory roles of the recently discovered long intervening non-coding RNAs (lincRNAs).

“This wide-reaching collaboration with the Broad Institute provides further validation for the strength of the NanoString technology platform and its promise for enabling research studies that would otherwise be difficult or cost-prohibitive,” said Wayne Burns, Acting Chief Executive Officer for NanoString Technologies. “One of the expected outcomes of this collaboration is to develop ways to make these types of molecular network analyses routine in studies of human disease.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Nanostring Technologies. (2019, March 18). NanoString Announces Collaboration with Broad Institute of MIT and Harvard. AZoNano. Retrieved on February 22, 2024 from https://www.azonano.com/news.aspx?newsID=14736.

  • MLA

    Nanostring Technologies. "NanoString Announces Collaboration with Broad Institute of MIT and Harvard". AZoNano. 22 February 2024. <https://www.azonano.com/news.aspx?newsID=14736>.

  • Chicago

    Nanostring Technologies. "NanoString Announces Collaboration with Broad Institute of MIT and Harvard". AZoNano. https://www.azonano.com/news.aspx?newsID=14736. (accessed February 22, 2024).

  • Harvard

    Nanostring Technologies. 2019. NanoString Announces Collaboration with Broad Institute of MIT and Harvard. AZoNano, viewed 22 February 2024, https://www.azonano.com/news.aspx?newsID=14736.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.